MedTrace Logo

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

NCT07402044 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-03-27

No results posted yet for this study

Summary

The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.

Conditions

  • CABOTEGRAVIR
  • LENACAPAVIR

Sponsors & Collaborators

  • INSERM UMR S 1136

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    collaborator OTHER_GOV

  • Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

    lead OTHER

Principal Investigators

  • Roland LANDMAN · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2028-03-15
Completion
2028-03-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402044 on ClinicalTrials.gov